Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Japan”
- A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing MyopathyNot Yet Recruiting
Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Refractory Immune-mediated Necrotizing Myopathy
China
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive Not Recruiting
Sponsor: Eli Lilly and Company
Prostate Cancer
United States, Australia, China, Denmark, France +6 more
Sponsor: Eli Lilly and Company
Juvenile Idiopathic Arthritis
Argentina, Australia, Austria, Belgium, Brazil +15 more
- Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Active Not Recruiting
Sponsor: Ultragenyx Pharmaceutical Inc
Angelman Syndrome
United States, Canada, Germany, Japan, Poland +1 more
Sponsor: AstraZeneca
Locally Advanced Head and Neck Squamous Cell Carcinoma
United States, Austria, Belgium, Brazil, Canada +18 more
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia
United States, Australia, Belgium, Estonia, Finland +4 more
- Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active Not Recruiting
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · Solid Tumors · Programmed Cell Death-1 (PD1, PD-1) · Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Japan
Sponsor: Eli Lilly and Company
Ovarian Neoplasms · Breast Neoplasms · Pancreatic Intraductal Neoplasms · Colorectal Neoplasms
United States, China, Germany, Japan, Netherlands
Sponsor: Sanofi
Atopic Dermatitis
United States, Canada, China, France, Italy +4 more
Sponsor: Bayer
Peripheral Arterial Disease (PAD)
Japan
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive Not Recruiting
Sponsor: AstraZeneca
Carcinoma · Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +22 more
Sponsor: Daiichi Sankyo
Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +18 more
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive Not Recruiting
Sponsor: AbbVie
Hematologic Cancer
United States, Canada, France, Germany, Israel +4 more
Sponsor: Eli Lilly and Company
Diabetes Mellitus, Type 1
United States, Australia, Belgium, Brazil, Canada +13 more
Sponsor: Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
United States, Argentina, Belgium, Bulgaria, Canada +15 more
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Recruiting
Sponsor: Eli Lilly and Company
Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies · Amyloid
United States, Japan, South Korea, Taiwan
Sponsor: Incyte Corporation
Chronic Graft-versus-host-disease
United States, Australia, Austria, Canada, Denmark +8 more
Sponsor: Amgen
Atopic Dermatitis
United States, Argentina, Australia, Austria, Belgium +21 more
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer · KRAS G12C Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +23 more
Sponsor: China-Japan Friendship Hospital
Gastroesophageal Reflux Disease (GERD)
China
Sponsor: China-Japan Friendship Hospital
Chronic Obstructive Pulmonary Disease
China
Sponsor: Bayer
Prostate Cancer
United States, Argentina, Austria, Belgium, Brazil +12 more
Sponsor: BeOne Medicines
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Argentina, Australia, Austria, Belgium +19 more
Sponsor: Incyte Corporation
Solid Tumors
United States, Australia, Austria, Belgium, Canada +15 more
Sponsor: Hoffmann-La Roche
Hemophilia A
United States, Germany, Hungary, Italy, Japan +5 more